EGFR and cancer: Moreover, EE02 did not result in significant suppression in normal cell lines (MCF-10A and BEAS-2B, less than 40% suppression) and peripheral blood mononuclear cells (PBMCs) from 5 untreated healthy volunteers (less than 30% suppression), suggesting that EE02 possesses specificity toward cancer cells that overexpress EGFR and EPS8 (Fig. 2d and e).